Latest Esg Initiatives News

Atlas Arteria reported a 32.9% drop in statutory net profit for H1 2025 due to a new French tax, yet achieved solid toll revenue and EBITDA growth, maintaining its 2025 distribution guidance.

SDI Limited’s FY25 results reveal steady revenue with improved margins driven by operational efficiencies and strong European and Brazilian sales. The company is progressing its Montrose facility project and advancing ESG initiatives.

Trajan Holdings delivered solid FY2025 results with revenue up 7.4% to $166.5 million and improved profitability despite transient costs and a biotech syringe loss. The company refinanced debt and set an optimistic FY2026 guidance range.

RAM Essential Services Property Fund (REP) posted a reduced net loss for FY25 alongside stable distributions and extended its debt facility to January 2027, maintaining a focus on essential healthcare and retail properties amid a cautious economic outlook.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Tyro Payments reported modest transaction growth and a 10.6% rise in EBITDA for FY25, while preparing for a CEO change and expanding into new industry verticals.

Johns Lyng Group reported a modest revenue increase to $1.18 billion in FY25, driven by organic growth and key acquisitions, while agreeing to a $1.1 billion takeover scheme with Pacific Equity Partners.

AUB Group Limited has reported a robust FY25 financial performance, highlighted by a 171% increase in underlying net profit after tax and a 15.2% rise in total dividends. Strategic acquisitions and organic growth across divisions underpin the company’s strong momentum.

Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.

Dalrymple Bay Infrastructure Limited (DBI) reports a strong first half of 2025 with increased funds from operations and distributions, underpinned by a stable, inflation-linked revenue model and significant capital investment in terminal maintenance and expansion.

Data # 3 Limited has delivered a robust FY25 performance with revenues rising 5.8% to $863 million and net profit up 11.3%, supported by strong growth across its core business segments and a 10.2% dividend increase.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.